← Eichor
Condition: Mammary Gland Hyperplasia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Mammary Gland Hyperplasia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Phase 2 · 3 location(s) · National Cancer Institute (NCI) · NCT06195306InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT05463796Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Develop
Phase 2 · 4 location(s) · National Cancer Institute (NCI) · NCT05941520Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Phase 2 · 11 location(s) · National Cancer Institute (NCI) · NCT06184750Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
Phase 3 · 27 location(s) · Tasly Pharmaceutical Group Co., Ltd · NCT06685978Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Phase N/A · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05178498Indications for Breast Reduction in the Public Health Care System
Phase N/A · 1 location(s) · Vastra Gotaland Region · NCT04889469
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.